文章：

循环肿瘤DNA作为肺癌预后与预测性生物标志物

Circulating Tumor DNA as a Prognostic and Predictive Biomarker in Lung Cancer

原文发布日期：15 October 2025

DOI: 10.3390/cancers17203327

类型: Article

开放获取: 是

英文摘要：

Background/Objectives:Lung cancer remains a leading cause of cancer-related mortality worldwide. In recent years, the development of liquid biopsy, or ctDNA detection in body fluids, particularly blood, has been shown to be effective in detection, genotyping, prognostication, and evaluating therapy response, particularly in non-small cell lung cancer (NSCLC).Methods:In this review, we present a summary of the current landscape of ctDNA, applications, and limitations, as well as future areas of research.Results/Conclusions:Though not yet in its prime, ctDNA detection and tracking have powerful current and potential uses, including treatment selection, prognostication, and risk stratification.

摘要翻译： 

背景/目的：肺癌仍是全球癌症相关死亡的主要原因。近年来，液体活检技术（即通过体液特别是血液进行循环肿瘤DNA检测）的发展，已被证明在肺癌（尤其是非小细胞肺癌）的检测、基因分型、预后评估及治疗反应监测方面具有显著效果。 方法：本文综述了当前循环肿瘤DNA的研究现状、临床应用、技术局限性以及未来研究方向。 结果/结论：尽管循环肿瘤DNA检测与追踪技术尚未臻于成熟，但其在当前及潜在临床应用领域——包括治疗方案选择、预后判断及风险分层等方面——已展现出强大的应用价值。

原文链接：

Circulating Tumor DNA as a Prognostic and Predictive Biomarker in Lung Cancer